The Scientist

January 1, 2017

By Anna Azvolinsky

An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications.

In 2010, Bruce Bloom, CEO of Illinois-based Cures Within Reach, reviewed the organization’s decade-long track record of bringing new treatments to patients. He found that the nonprofit had funded 190 novel drug projects, but “couldn’t find any instance where it was directly helping patients,” says Bloom. Cures Within Reach had also funded 10 different drug repurposing projects, seeking to test existing drugs for novel indications. Of the 10 projects, four generated enough evidence to give physicians confidence to treat patients off-label, which doctors can do at their discretion, particularly when there is no approved therapy for a condition or when a patient has exhausted all available treatment options.

“We then polled 200 researchers and clinicians, and 66 percent of researchers told us they had a [repurposing] project ready for investigation, and 25 percent of clinicians had clinical observations they wanted to test in a trial,” says Bloom. “This convinced us that there is a ton [of opportunities] out there for repurposing.”

 

Read the full article here

 

Sign up for our eNewsletter today!

 

First Name




Search

Cures Within Reach

info@cureswithinreach.org

 

Thursday the 14th. copyright 2015 Cures Within Reach.